Analyst Upgrades

• Piper Jaffray upgraded Edwards Lifesciences (EW) to overweight from neutral and raised its target price for shares to $77 from $53 after The New England Journal of Medicine reported the company's PARTNER Trial met primary endpoints.
• UBS upgraded Endo Pharmaceuticals (ENDP) to buy from neutral and raised its price target to $36 from $25. UBS is positive on Endo's creative strategic deals and believes the switch to Opana TRF from Opana ER will be easy. Additionally, the analyst believes pipeline expectations are very low.
• BMO Capital upgraded Nvidia (NVDA) to outperform from market perform based on expectations that share loss in the core GPU business will stop, Tegra momentum and valuation. The firm raised its price target to $16 from $9.
• FirstEnergy (FE) and Allegheny Energy (AYE) were upgraded to outperform from neutral at Credit Suisse.
• Mylan (MYL) was upgraded to conviction buy from buy at Goldman. Warner
• Chilcott (WCRX) was upgraded to overweight from equal weight at Morgan Stanley.

Tuesday morning, drugmaker Mylan (MYL) announced that the Food and Drug Administration (FDA) granted regulatory approval for a generic version of Arimidex, which is produced by AstraZeneca (AZN).

Reportedly, the FDA approved 1-milligram tablets of anastrozole, which is the active ingredient in AstraZeneca's Arimidex. Anastrozole is used to treat some breast cancer in postmenopausal women. This news follows Tueday's approval of a generic version of Arimidex that is produced by Teva Pharmaceutical (TEVA).

GlaxoSmithKline (GSK - option chain) stock is trading lower Wednesday after competitor Mylan (MYL) received approval to start selling a generic form of GSK's herpes drug Valtrex. If you think this stock won't be rising too far in the coming months, then it could be a good time to look at a bearish hedged play on GSK.

Wednesday morning, GSK opened at $32.62. So far today the stock has hit a high of $32.91 and a low of $32.52. As of 11:30, GSK is trading at $32.58, down $0.34 (-1.0%). The chart for GSK looks neutral and S&P gives GSK a neutral 3 STARS (out of 5) hold ranking.

Analyst Upgrades

• Deutsche Bank upgraded United Parcel Service (UPS) to buy from hold on expectations the company will benefit from improving international package volumes and restructuring initiatives. The firm raised its target on shares to $70 from $67.
• JPMorgan upgraded SVB Financial (SIVB) to overweight from neutral on valuation following the recent pullback in shares. The firm has a $54 price target on the stock.
• Baird upgraded ArvinMeritor (ARM) to outperform from neutral and raised its target to $15 from $12 following the Q2 report. The firm said ArvinMeritor has transformed its business model and is well-positioned for growth.
• UBS (UBS) was upgraded to overweight from neutral at JPMorgan.
• Occidental Petroleum (OXY) was upgraded to conviction buy from buy at Goldman.
• Vail Resorts (MTN) was upgraded to outperform from market perform at Wells Fargo.

Analyst Upgrades

• Stephens upgraded Martin Marietta (MLM) to overweight from equal weight on valuation and expectations that infrastructure and highway spending will increase. The firm raised its target on shares to $105 from $95.
• Janney Montgomery upgraded Shutterfly (SFLY) to buy from neutral to reflect valuation and a reduced pricing overhang after Kodak (EK) raised its 4x6 prices. The firm raised its target on shares to $21 from $18.
• Thomas Weisel upgraded Entropic Communications (ENTR) to overweight from market weight. The firm thinks the company is well-positioned for revenue growth in 2010, partly due to MoCA deployments from new customers and design wins for its silicon tuner product. The firm set a $5 target.
• T. Rowe Price (TROW) was upgraded to buy from hold at Jefferies.
• Dick's Sporting Goods (DKS) was upgraded to buy from neutral at BofA/Merrill.
• Massey Energy (MEE) was upgraded to overweight from neutral at JPMorgan.

Here are some highlights from last week's earnings coverage from BloggingStocks:

• Aetna Inc. (NYSE: AET) reported better-than-expected Q3 earnings and revenue, sending shares higher.
• Allergan Inc. (NYSE: AGN) reported better-than-expected Q3 numbers, sending shares higher.
• Bare Escentuals Inc. (NASDAQ: BARE) Q3 profit easily topped analysts' estimates, and shares surged.
• Cabot Oil & Gas Corp. (NYSE: COG) received an upgrade following the release of its Q3 numbers.
• Estee Lauder Companies Inc. (NYSE: EL) reported strong Q1 results, sending shares higher.
• E*Trade Financial Corp. (NASDAQ: ETFC) reported a smaller-than-expected net loss for Q3.
• Goodyear Tire & Rubber Co. (NYSE: GT) Q3 earnings topped estimates and revenue was up sequentially.

One would expect generic U.S. drugmaker Mylan (NYSE: MYL) to benefit from all this talk about increased generic competitions, but revenue only increased 5.2 percent to $1.26 billion on an operational basis, beating analyst revenue estimates of $1.23 billion. Still, revenue in North America, where most pharmas have been hurting, rose 9.2 percent to $502.5 million, helped by new product launches and increased volume.

On an adjusted basis, Mylan posted better-than-expected third-quarter results on Thursday, reporting an earnings per share of 32 cents -- 5 cents higher than the average estimate of analysts polled by Thomson Reuters I/B/E/S. It seems that just like branded pharmas, Mylan benefited from cost cuts. Still, the world's No. 3 generic drugmaker raised its full-year outlook and said it believes it can continue its current momentum into 2010.

This was an interesting day in the markets. The market opened higher because of yesterday's recovery, but slid from the open. And it slid lower most of the day. Commodities fell again on worries that the economy isn't far enough along to support higher prices, and possible regulation on the size of speculators continued to hamper prices.

T. Boone Pickens gave bullish oil forecasting today, but compared to the past it wasn't that bullish. There was no major economic data for the markets to chew today, just a continued paring down of expectations ahead of earnings season. Here were the unofficial closing bell levels:

Dow 8,162.39 -162.48 (-1.95%)
S&P 500 880.96 -17.76 (-1.98%)
Nasdaq 1,746.17 -41.23 (-2.31%)

Top Analyst Calls

Today marked intra-day 2009 for the S&P 500 and NASDAQ, although these might not have closed on the highs for the year. Also that won't be known until the formal 4:30-ish closing reset adjustment. This came on the heels of slightly less-bad jobs data and on some confusing retail gains. Unlike earlier Treasury auctions, today's 30-year Treasury Bond auction was a help to the markets as yields reached a high enough level that investors jumped in. Here are today's unofficial closing bell levels:

Dow 8,770.92 +31.90 (0.37%)
S&P 500 944.88 +5.73 (0.61%)
Nasdaq 1,862.37 +9.29 (0.50%)

Top Analyst Upgrades
Top Analyst Downgrades

Analyst upgrades:

• Goldman upgraded SanDisk (NASDAQ: SNDK) to Buy from Neutral and raised their target to $22 from $16 citing the renegotiated royalty agreement with Samsung.
• Goldman also upgraded Starwood Hotels (NYSE: HOT) to Buy from Sell and raised their target to $27 from $11 citing strong operating leverage as RevPAR recovers.
• KeyBanc upgraded Werner Enterprises (NASDAQ: WERN) to Hold from Underweight citing a recent improvement in freight demand.
• J.C. Penney (NYSE: JCP) was upgraded to buy from Underperform at Banc of America/Merrill.
• Savvis (NASDAQ: SVVS) was raised to Outperform from Perform at Oppenheimer.
• Sanofi-Aventis (NYSE: SNY) was upgraded at Citigroup to Buy from Hold.

"Few industries seem as well positioned for future growth as the generic drug industry," says small-cap growth stock specialist Tom Bishop.

In his BI Research newsletter, he explains, "With demographic pointing to an increasingly aging population, and healthcare costs spiraling out of control, low cost generic drugs are clearly part of the solution." Here's a look at generic drug maker Mylan (NYSE: MYL).

"High on the agenda of the Obama administration is to bring health care coverage to some 40 million Americans who are currently not covered.

Analyst upgrades:

• Bernstein upgraded Merck (NYSE: MRK) to Outperform from Market Perform and raised its target to $30 from $27 citing valuation and its decision to buy Schering-Plough, at what appears to be a reasonable price.
  
• RBC Capital upgraded Palm (NASDAQ: PALM) to Outperform from Sector Perform and raised its target to $12 from $5 as it believes webOS has increased its chances for Smartphone leadership and will increase its attractiveness as an acquisition target.
  
• RW Baird upgraded Alcatel-Lucent (NYSE: ALU) to Outperform from Neutral on valuation as it believes balance sheet risks are overly discounted in the stock, creating a buying opportunity. The firm has a $3 target on shares.
• Express Scripts (NASDAQ: ESRX) was raised to Buy from Hold at Argus.
  
• France Telecom (NYSE: FTE) was upgraded at Morgan Stanley to Equal Weight from Underweight.
  
• Foster Wheeler (NASDAQ: FWLT) was upgraded to Conviction Buy from Neutral at Goldman.

Analyst upgrades:

• Banc of America/Merrill upgraded DPL Inc (NYSE: DPL) to Neutral from Underperform following the settlement agreement with staff of the Public Utilities Commission of Ohio on Electric Security Plan.
  
• Friedman Billings upgraded SeaBright Insurance (NYSE: SBX) to Outperform from Market Perform on valuation as they believe shares are oversold at current levels. Despite upgrading, the firm lowered its target price to $14 from $16.
  
• JP Morgan upgraded AT&T (T) to Overweight from Neutral as it believes upside earnings revisions are likely in 2009 due to the company's conservative wireline margin outlook. The firm finds the stock's valuation attractive at current levels and raised their target on shares to $28 from $24.
• Chubb (NYSE: CB) was upgraded to buy from Neutral at UBS.
  
• Cascal B.V. (NYSE: HOO) was raised to Outperform from Neutral at Credit Suisse.
  
• Healthcare Realty Trust (NYSE: HR) was upgraded at Keefe Bruyette to Outperform from Market Perform.

Analyst upgrades:

• Citigroup upgraded Blue Nile (NASDAQ: NILE) shares to Buy from Hold on valuation following the recent sell-off as they believe weakening fundamentals have been factored into estimates and that Blue Nile should benefit from the recent softening of diamond prices. The firm raised its target price to $30 from $20.
  
• Baird upgraded AmSurg (NASDAQ: AMSG) to Outperform from Neutral based on valuation, potential upside from in-line results, good visibility, and FCF yield.
  
• Oppenheimer upgraded DryShips (NASDAQ: DRYS) to Perform from Underperform on valuation following the recent weakness and believes the company is at least halfway through its $500M equity offering.
• UAL Corp (NASDAQ: UAUA) was raised to Buy from Neutral at Banc of America/Merrill.
  
• Mylan (NASDAQ: MYL) was upgraded to Overweight from Equal Weight at Barclays.
  
• Exxon Mobil (NYSE: XOM) was lifted at Deutsche Bank to Buy from Hold.

Analyst upgrades:

• Goldman added McDonald's (NYSE:MCD) to its Conviction Buy List as they believe the company will beat their earnings expectations over the next couple quarters. Note that Burger King (NYSE:BKC) was removed from the list.
  
• Baird upgraded Woodward Govenor (NASDAQ:WGOV) to Outperform from Neutral citing increased confident in its outlook following the better-than-expected Q1 report.
  
• Citigroup upgraded Harley-Davidson (NYSE:HOG) to Hold from Sell and removed shares from their Top Picks Live List as a Sell as they believe current expectations are very low following the recent weakness. Citigroup lowered their target price to $13 from $18.
• Ford (NYSE:F) and Lear (NYSE:LEA) were upgraded to Hold from Sell at Deutsche Bank.
  
• KT Corp (NYSE:KTC) was raised to Overweight from Neutral at HSBC.
  
• Ryanair (NASDAQ:RYAAY) was upgraded to Hold from Sell at Collins Stewart and to Buy from Neutral at UBS.

Analyst downgrades:

• Goldman removed Burger King (NYSE:BKC) from its Conviction Buy List citing recent share strength. Note that McDonald's (NYSE:MCD) was added to the list.
  
• Keefe Bruyette downgraded shares of Och-Ziff Capital (NYSE:OZM) to Market Perform from Outperform to reflect the company's near-term headwinds. The firm lowered their target to $5 from $6.50.
  
• Morgan Stanley downgraded Freeport-McMoRan (NYSE:FCX), Alcoa (NYSE:AA), and Century Aluminum (NASDAQ:CENX) to Equal Weight from Overweight as they believe industrial metals will be depressed through next year.
• Air France (Other OTC:AFLYY) was downgraded to Sell from Neutral at UBS.
  
• Wal-Mart (NYSE:WMT) was lowered to Neutral from Outperform at Credit Suisse.
  
• Radware (NASDAQ:RDWR) was cut at Argus to Hold from Buy.

Analyst initiations:

• Merriman initiated Suntech (NYSE:STP) with a Sell rating. The firm is concerned by the company's debt load and narrowing maturity and thinks further cost reduction in China could be a challenge. The firm believes a fair price target range is $3.50-$4.50 per share.
  
• JMP Securities views Google (NASDAQ:GOOG) as a long-term "must buy" given its dominant market position, strong balance sheet, and low valuation. Shares were initiated with an Outperform rating and $400 target.
  
• Auriga started Micron (NYSE:MU) with a Buy rating and $5 target. The firm expects DRAM oversupply to ease in the second half of 2009 and believes Micron will not burn significant cash this year.
• Qualcomm (NASDAQ:QCOM) was initiated at Morgan Stanley with an Equal Weight rating and $41 target.
  
• Core Laboratories (NYSE:CLB) was initiated with a Buy rating and $80 target at Wunderlich.
  
• Mylan (NASDAQ:MYL) was started with a Buy rating and $16 target at Citigroup.